CAJ | 학술논문

出血是目前临床抗栓药物防治最主要、最常见的并发症。近年来，有关凝血因子XI（FXI）与血栓性疾病发生相关的临床资料、FXI基因敲除动物或抑制FXI的抗栓实验均表明FXI是出血风险小的抗栓防治新靶点，针对FXI靶点的抗栓药物出血副作用小。
출혈시목전림상항전약물방치최주요、최상견적병발증。근년래，유관응혈인자XI（FXI）여혈전성질병발생상관적림상자료、FXI기인고제동물혹억제FXI적항전실험균표명FXI시출혈풍험소적항전방치신파점，침대FXI파점적항전약물출혈부작용소。
Thromboembolic diseases are major health problems worldwide,and remain the leading cause of mortality and disabil-ity at present.Bleeding is the most important complication of an-tithrombotic therapy for thromboembolism,therefore research and development of new antithrombotic drugs with lowered bleeding risk is a significant medical need.The data that elevated plasma levels of FXI are associated with thromboembolic diseases,se-vere FXI deficiency reduced incidence of DVT and ischemic stroke,and FXI deficiency or inhibition in animals shows protec-tive effects against thrombus formation supporting FXI as a novel antithrombotic target with lowered bleeding risk.This paper re-views the progress on FXI as a novel antithrombotic target and the inhibitors target FXI.